AZN vs CELC
AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline. CELC: Celcuity is developing gedatolisib, a comprehensive PI3K/AKT/mTOR pathway inhibitor in Phase 3 trials for hormone receptor-positive breast cancer and metastatic prostate cancer.
Side-by-side fundamentals
| Metric | AZN | CELC | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $169.73 | $90.14 | |
| Market cap as of 2026-07-23 | $193.7B | $4.4B | |
| P/E as of 2026-07-23 | 24.93 | n/a | |
| PEG as of 2026-07-23 | 2.64 | -0.82 | CELC lower |
| Net margin as of 2026-07-23 | +17.2% | n/a | |
| Gross margin as of 2026-07-23 | +81.4% | n/a | |
| Operating margin as of 2026-07-23 | +23.7% | n/a | |
| ROE as of 2026-07-23 | +22.3% | -244.6% | AZN higher |
| ROA as of 2026-07-23 | +9.1% | -50.2% | AZN higher |
| Debt / equity as of 2026-07-23 | 0.72 | 6.04 | AZN lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | n/a | |
| Dividend yield as of 2026-07-23 | +1.9% | n/a | |
| Beta as of 2026-07-23 | 1.38 | 0.20 | |
| 1-year return as of 2026-07-22 close | +17.0% | +546.6% | CELC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.